Verified July 2026 · Cited to primary sources
MOTS-c: Evidence Grade D — Animal studies only, unproven in humans.
The honest verdict
MOTS-c is not FDA-approved and is under FDA review (July 23, 2026 PCAC). Human evidence is Grade D — metabolic effects are mostly preclinical, with human data limited to associations. For actual weight loss, an approved GLP-1 is the evidence-backed route.
MOTS-c at a glance
- Class
- Mitochondrial-derived peptide (16-aa)
- Mechanism
- Mitochondrial-derived "exercise mimetic" that activates AMPK to improve insulin sensitivity and metabolic homeostasis in preclinical models.
- Also known as
- Mitochondrial ORF of the 12S rRNA type-c
- Research applications
- Metabolic health / insulin sensitivity (preclinical)
- Weight/fat loss and exercise performance (marketed; human data association-only)
- Forms
- subcutaneous injection
- Legal status
- Under FDA review
- WADA (anti-doping)
- UNKNOWN (not explicitly listed; possibly S0 or S4 — verify)
- Evidence grade
- Grade DAnimal studies only, unproven in humans
How we grade evidence
Every grade is assigned by a fixed A–F rubric — human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is MOTS-c?
An "exercise-mimetic" metabolic peptide — real mechanistic interest, but human evidence is association-only.
Mitochondrial-derived "exercise mimetic" that activates AMPK to improve insulin sensitivity and metabolic homeostasis in preclinical models.
How strong is the evidence for MOTS-c?
Grade D: preclinical plus early human observational/biomarker studies, no efficacy RCT (rule 5 fired).
Primary sources (2)
Is MOTS-c legal? (Status July 2026)
Regulatory limbo — July 2026 PCAC vote pending.
On the July 2026 PCAC docket
MOTS-cis one of the seven peptides the FDA's Pharmacy Compounding Advisory Committee reviews on July 23–24, 2026. Its legal compounding status could change after that vote. Track the FDA peptide vote →
What is MOTS-c used for?
MOTS-c is marketed for the goals below. See how it ranks against other peptides in each — by evidence, not hype.
What does MOTS-c cost — and how do you access it legally?
Typical cost
UNKNOWN
No verified clinic price anchor in the research; marked UNKNOWN.
No legal supervised access route right now.
MOTS-c has no compliant US route today while its compounding status is under FDA review. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole — we don't link them. If you pursue MOTS-c, do it with a licensed clinician, and re-check its legal status first.
Trying to lose weight?
For weight loss, an approved GLP-1 beats this peptide.
No research peptide here has proven, legally-available weight-loss data that beats an approved GLP-1. Our sister site compares the options that actually work.
Is MOTS-csafe? Side effects & risks
Minimal human safety data; unknown long-term effects. WADA classification not explicitly listed — likely captured under S0 or S4 (metabolic modulators); verify before relying on it.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
FAQ
MOTS-c FAQ
Does MOTS-c help with weight loss?
MOTS-c improves metabolism and insulin sensitivity in animal models and is marketed as an "exercise mimetic," but human evidence is association-only — Grade D. If weight loss is the goal, approved GLP-1 medications have the human trial data. See our weight-loss guidance.
Is MOTS-c FDA approved?
No. MOTS-c is not FDA-approved and is under FDA review — it is one of the seven peptides on the July 23, 2026 PCAC docket.
Compare MOTS-c with…
Head-to-head evidence-grade matchups people weigh against MOTS-c.
Keep reading
Tesamorelin
One of only two FDA-approved peptides in this space — proven to cut visceral fat, but approved for a narrow HIV indication.
Grade BRetatrutide
The next-generation weight-loss peptide with the strongest efficacy signal — but it is investigational and not yet available by any legal route.
Grade APT-141
One of only two FDA-approved peptides in this space — proven to raise sexual desire in premenopausal women, but the benefit is modest and the off-label hype outruns it.
The monthly peptide evidence brief.
What the research and the FDA actually say — one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.